Implantable Osmotic Release Pump

$290.00

  • Ensures continuous and uninterrupted administration, maintenance and constant administration of a drug to an animal
  • Storage capsules have good drug compatibility and protection for short half-life drugs
  • Capsules have good biocompatibility and do not affect the physiology of animals
  • Single administration per experiment for ease of use
  • Avoid the stress of repeated administration of drugs, reducing the impact of non-experimental factors on the experimental results
  • Its compact size can be applied to experiments on mice, neonatal rats or other small animals
    Ensures that the drug is delivered to the target site accurately

Introduction

The implantable osmotic release pump is an inexpensive cutting-edge drug delivery system. You can use this small implantable infusion pump for preclinical pharmaceutical research in mice, rats, and other laboratory animals. The mini-pump delivers drugs, hormones, and other test compounds at continuous and controlled rates, for terms extending from one day to a month and a half, without the requirement for external interference. The implantable pumps utilize osmosis for continuous infusion of unrestrained laboratory animals.

In the previous three decades, the drug delivery research has made critical headways because of the recent developments and innovations in the fields of pharmaceutical sciences including pharmacokinetics, pharmacodynamics, and biopharmaceutics. Low development cost and regulated drug delivery pushed the research. Hence a significant portion of the novel drug delivery frameworks is upgraded such that the drug dose and dosing interim are reduced thereby maintaining optimum therapeutic dose and efficacy. These innovative drug delivery systems have been designed to regulate the drug release over an extended time-frame. Furthermore, recent advances have been made to make the rate and extent of the drug release independent of physicochemical properties of drugs and excipients, and physiological factors like pH of the gastrointestinal tract, the presence of food, and nutritional health.

Osmotic pumps are the most promising procedure based systems for controlled drug delivery. The controlled drug delivery system is mediated by osmosis which can be characterized as the net movement of water molecules over a selectively permeable film driven by a difference in osmotic gradient over the layer. The difference in solute concentration over the membrane permits entry of water, however, rejects most solute particles. Osmogens create osmotic pressure to stimulate drug release from the pump.

Specifications

CapsuleDrug Capacity100ul200ul2ml
Cycle3d7d2w4w10d1w2w4w6w1w2w4w
Injection Rate (ul/hr)1.00.50.250.118.01.00.50.250.1510.05.02.5
Flow regulatorCapPolyethylene material , variety of colors optional, removes air and prevents leakage
Draft Tube304 Stainless Steel Material
Infusion tubeSyringeFlat head for the injection of liquid

Apparatus And Equipment

In cross-section, the implantable osmotic release pumps are composed of a drug core (reservoir), the diffusion agent, and the tissue layer (rate controller). Additionally, a flow moderator is inserted into the body of the diffusion pump. It is a kind of an implantable system within which you can load a solution or suspension contained in a cylindrical reservoir shaped from an artificial collapsible, impervious stuff wall (e.g., polyester) that is open to the external surroundings via a single orifice.

Main components of an implantable osmotic release pump include the drug compound (water-soluble or insoluble), osmotic agents (ionic compounds of inorganic salts), a stable semi-permeable membrane, plasticizers, flux regulators, wicking agents, pore forming agent, and coating solvent.

Our implantable osmotic release pump is available in three different sizes to offer the researchers with a variety of dosing capacity, release rates, and duration. You can load it with 100 µl, 200 µl, and 2 ml of the test compound.

Get in Touch
Questions? Concerns? Need a Quote?

Principle

The implantable osmotic pump employ osmotic gradient inside the lumen called the salt sleeve and the tissue condition in which the pump is implanted. The high osmolality of the salt sleeve makes water flow into the pump through a semipermeable film which encases the external surface of the pump. As the water enters the salt sleeve, it compresses the flexible reservoir, dislodging the test substance from the tube at a controlled rate. The rate of drug delivery is directly proportional to the osmotic pressure of the core. Since the delivery system cannot be refilled, these pumps are intended for single-use only.

The rate of the drug delivery by our osmotic pump is controlled by the water penetrability from the pump’s external film. In this manner, the drug delivery is independent of the drug formulation and excipients. Drugs of different atomic arrangements, including ionized medications and macromolecules, can be administered persistently at controlled rates. The sub-atomic weight of a compound, or its physical and chemical properties, does not affect the rate of the drug delivery by the implantable osmotic release pumps.

Procedure

The osmotic pumps can be implanted subcutaneously or intraperitoneally depending on the size of the animal. For targeted drug delivery, a catheter can be attached to the osmotic pump to gain access to the tissues of interest. Subcutaneous implantation is technically the easiest and least intrusive procedure. Follow these steps for subcutaneous implantation:

  1. Anesthetize the animal with ketamine or any other rodent anesthetizer.
  2. Shave and wash the skin over the implantation site.
  3. Make an incision adjacent to the implantation site. If the implantation is planned on the back side of the animal, then the mid-scapular incision is made.
  4. To avoid excessive blood flow, place a hemostat onto the incision. Make an appropriate pocket for the pump by manipulating the subcutaneous tissues by hemostat. Keep in mind that the pocket should be large enough to allow the pump movement.
  5. Insert the pump containing the drug into the pocket in the incision.
  6. With the help of incision clips, close the wound.

The osmotic system can also be implanted in the peritoneal cavity of the larger animals. Follow the below-mentioned protocol for intraperitoneal injection:

  1. After anesthetizing the animal, shave and wash the skin over the implantation site.
  2. In the lower abdomen, make a 1 cm long midline skin incision.
  3. Tent the peritoneal muscles and carefully incise the peritoneal wall keeping the bowel safe.
  4. Insert the osmotic pump in the cavity.
  5. Close the abdomen with the help of sutures and incision clips.

Keep in mind that the pumps should be explanted if the animals survive after active infusion. The pumps must be removed no later than the first half-life of the test compound.  The pump should be removed to measure the residual volume to confirm delivery, to verify a drug’s stability, and to assure the bioactivity of the test compound.

Applications

Implantable consistent infusion osmotic pumps have many applications in preclinical drug delivery improvement. The system empowers continuous and controlled dosing permitting the accomplishment of enduring state conditions and precise drug delivery. The system offers the researchers with temporal and spatial control over the drug release. It circumvents poor-availability hurdles in the challenging therapeutic studies of hormones and growth factors. Also, the drugs with faster clearance rates and shorter half-lives require a consistent dosage that can be easily achieved by the implantable osmotic release pumps. Furthermore, it can assist the drug delivery of the compounds having a lower therapeutic index by continuous infusion while avoiding toxic concentrations. Moreover, the osmotic systems not only deliver the drugs with moderate solubility but also with extreme solubility.

Continuous infusion of the therapeutic compounds with the help of the implantable osmotic release pump assist the experimenters to establish parameters of the drugs with unknown pharmacokinetics. These pumps can also be used for a comparative study of the efficacy of different drugs administered through different routes. In addition to the drug efficacy analysis, these drug delivery systems can also be used for targeted delivery of chemotherapeutic agents to the tumors with the help of an attached catheter. The osmotic release pumps can not only be used for chemotherapeutic preclinical studies but also to monitor cell proliferation to assess the carcinogenic potential of the cells. Also, these pumps improve bio-luminescence imaging studies by continuously delivering bio-luminescent substrates.

Applications of the osmotic release pump include the disciplines of oncology, stem cell research, gene transfection, gene silencing, neuroscience research, and preclinical pharmacological studies.

Strengths And Weaknesses

  • The osmotic release pump ensures round-the-clock delivery of the test molecules at a controlled rate.
  • Zero-order drug release after an initial tag is one of the significant advantages of the implantable osmotic release pump.
  • The tool offers drug delivery independent of physiological factors like gastric health, pH, and hydrodynamic conditions.
  • The drug release can be easily controlled by regulating the amount of water filled in the pump.
  • The equipment permits continuous and regulated administration of short peptides and proteins.
  • It offers a convenient method for the persistent dosing of laboratory animals.
  • It minimizes unwanted experimental variables and makes sure reproducible, constant results.
  • It eliminates the need for nighttime or weekend dosing.
  • Its small size increases its popularity for use in mice and small rats.
  • The osmotic drug delivery system allows for focused and targeted drug administration.
  • It can be used for both in-vivo and in-vitro studies.
  • It provides the biomedical researchers with cost-effective research tool.
  • There may be a chance of dose dumping if the film coating is not correct.
  • The size of the orifice is critical for controlled drug release.
  • It may cause ulceration or irritation at the site of implantation.

Osmotic pumps are one of the novel pharmaceutical tools for controlled and consistent drug delivery. Osmotic drug delivery pumps commonly comprise a drug center containing osmogen that is covered with a semipermeable layer. This covering has at least one transportation ports through which the test compound or suspension of the medication is discharged after some time. Different endeavors are underway to make an effective osmotic drug delivery system like pulsatile delivery with an expandable hole, and lipid osmotic pump containing smaller capsule than the usual osmotic pump for continuous and extended release.

References

Continuous Drug Infusion Model with an Implantable Osmotic Pump. Retrieved from: https://noblelifesci.com/uploads/file/Noble%20Life%20SciencesContinuous%20Infusion%20Model.pdf

Keraliya, R. A., Patel, C., Patel, P., Keraliya, V., Soni, T. G., Patel, R. C., & Patel., M. M. (2012). Osmotic Drug Delivery System as a Part of Modified Release Dosage Form. ISRN Pharmaceutics.

Mathur, M., & Mishra, R. A review on osmotic pump drug delivery system. International journal of pharmaceutical sciences and research.

Popesko, P., et al. (1992) A color atlas of small laboratory animals, Volume Two, Rat, Mouse & Hamster, London: Wolf Publishing Ltd.

Prescott LF. Novel Drug Delivery and Its Therapeutic application. West Susset, UK: John Wiley and Sons; 1989. The need for improved drug delivery in clinical practice; pp. 1–11.

Stepkowski, S. M., Tu, Y., Condon, T. P., Bennett, C. F. (1994) ‘Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities‘, Journal of Immunology, 153, 5336-5346.

Tu, Y., Stepkowski, S. M., Chou, T.-C., Kahan, B. D. (1995) ‘The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice,’ Transplantation, 59(2), 177-183.

Contact

Additional information

Title

Default Title